Skip to content.

Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical

Date Closed

November 4, 2021

Lead Office

Québec City


407.50 Million USD

On November 4, 2021, Aptose Biosciences Inc. announced they have entered into an exclusive license agreement with Hanmi Pharmaceutical to develop and commercialize HM43239. Under the terms of the agreement, Aptose has been granted exclusive rights to develop and commercialize HM43239, and Hanmi will receive an upfront payment of US$12.5 million as well as up to US$407.5 million in future milestone payments contingent upon the achievement of certain clinical, regulatory and sales milestones across several potential indications, as well as tiered royalties on net sales. HM43239 is an oral, clinical-stage myeloid kinome inhibitor (MKI) designed to target kinases operative in myeloid malignancies, and has shown promising responses in patients with relapsed or refractory acute myeloid leukemia.

Aptose Biosciences, headquartered in Toronto, Ontario, is a clinical-stage biotechnology company. It focuses on the discovery, research and development of anti-cancer therapies.

McCarthy Tétrault advised Aptose Biosciences with a team led by Charles-Antoine Soulière that included Farhiyah Shariff.